CC
BMRN icon

Coastland Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Coastland Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,900
Closed -$260K – 193
2015
Q2 		$260K Sell
1,900
-27,400
-94% -$3.4M 0.01% 189
2015
Q1 		$3.65M Buy
+29,300
New +$3.1M 0.12% 117

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Coastland Capital's BMRN Position: Q3 2015 in Review

Coastland Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 19,507 shares — an estimated $2.67M sold.

Coastland Capital first reported a position in BMRN in Q2 2014 and held it in 5 quarters. The position peaked at $7.7M in Q4 2014. 394 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

  • Coastland Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Coastland Capital sold 19,507 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $2.67M.
  • Coastland Capital first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 5 quarters.
  • Coastland Capital's BioMarin Pharmaceuticals position peaked at $7.7M in Q4 2014.
  • 394 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Coastland Capital's 13F filing for Q3 2015, filed 16 Nov 2015.